论文部分内容阅读
本文采用随机双盲对照试验评价西咪替丁(CIM)对原发性消化不良的疗效。方法 56例原发性消化不良病人,所有病人症状持续至少1个月。研究期间,除允许用抗酸剂外,未服其他抗消化不良药。将病人随机分为CIM组(27例)和安慰剂组(29例),服用剂量均为400mg每日2次,共4周。结果给药2周和4周后,CIM组病人的腹痛缓解率明显高于安慰剂组(63%对34%,p<0.05,和69%对38%,p<0.05),病人感到“很好或好”的百分数也较安慰剂高。给药期间,CIM对间歇性腹痛的效果优于持
This randomized, double-blind, controlled trial evaluated the efficacy of cimetidine (CIM) on primary dyspepsia. Methods 56 patients with primary dyspepsia, all patients with symptoms persist for at least 1 month. During the study, in addition to allowing antacids, did not take other anti-indigestion drugs. The patients were randomly divided into CIM group (n = 27) and placebo group (n = 29), taking 400 mg twice daily for 4 weeks. Results After 2 and 4 weeks of treatment, the remission rate was significantly higher in patients in the CIM group than in the placebo group (63% vs. 34%, p <0.05, and 69% vs 38%, p <0.05) The percentage of “good or good” was also higher than placebo. CIM’s effect on intermittent abdominal pain was better than that on dosing during dosing